Amicus Therapeutics Inc (LTS:0HF9)
$ 10.0592 0.0812 (0.81%) Market Cap: 2.98 Bil Enterprise Value: 3.17 Bil PE Ratio: 0 PB Ratio: 16.66 GF Score: 81/100

Amicus Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 14, 2022 / 04:20PM GMT
Release Date Price: $11.09
Andrew Francis Galler
Morgan Stanley, Research Division - Equity Analyst

All right. Good afternoon, everyone. I'm Andrew Geller, one of the biotech analysts here at Morgan Stanley, and I'm pleased to be joined by Brad Campbell, President and CEO of Amicus Therapeutics.

Brad, thanks for joining us today.

Bradley L. Campbell
Amicus Therapeutics, Inc. - CEO, President & Director

Yes. Thanks, Andrew. Thanks to Morgan Stanley for hosting us today. And a great...

Andrew Francis Galler
Morgan Stanley, Research Division - Equity Analyst

Just before we start, I have to read some disclosure statements.

Bradley L. Campbell
Amicus Therapeutics, Inc. - CEO, President & Director

Please go ahead.

Andrew Francis Galler
Morgan Stanley, Research Division - Equity Analyst

So for important disclosures, please see the Morgan Stanley research disclosure website at

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot